1Y Target$41.23Near-term target
5Y Target$45.56Compound horizon
10Y Target$66.97Long-dated conviction
FCF$3.0bTTM · 03/26BFCF $3.0b — solid, comfortably covers operations and capital return · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+60.8%TTM YoYARevenue +60.8% — hypergrowth, top decile
D/E0.08AD/E 0.08 — essentially debt-free, pristine balance sheet
P/E12.0xB+P/E 12.0 — at or below S&P median, reasonable
PEG1.12B+PEG 1.12 — near fair value, classic Lynch benchmark (1.0)
Why now
Gold · market cap $33.8b. Down 28% from 52-week high of $39.11 — deep drawdown territory. Revenue growing +61% — in hypergrowth territory. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $41.23 (implying +46% upside).
Moat
Net margin 36% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 106% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Reserve-replacement treadmill — every barrel or ounce extracted has to be replaced through exploration or acquisition; underspending on replacement reserves shows up in production declines 2-3 years out.
Horizon
1-3 yr $41.23 (11-analyst consensus) — fundamentals + valuation re-rating. 5 yr $45.56 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $66.97 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.